Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

ABSTRACT:

Background and objectives

Cladribine tablets (CladT) represent an effective immune reconstitution therapy, administered in short treatment courses over two consecutive years. To better understand the amplitude of immune changes, we performed a comprehensive analysis during the 2-year study period for the entire MAGNIFY-MS population (N=270). In addition to lymphocyte kinetics, we studied intracellular cytokines serum proteins, and their associations with clinical outcomes. To put these changes into perspective, we analyzed transcriptional changes in T and B cells and associated biological pathways before and after each treatment course with CladT.

Methods

Immunophenotyping and transcriptomics were performed at regular visits with major differences reported between baseline (

SUBMITTER: Wiendl H 

PROVIDER: S-EPMC11830603 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature